

Table 3: Evaluation of the utility of individual items on the IBS-QOL-J

Domain	Item	Correlation	Domain	Item	Correlation	
Dysphoria	Q1	-0.83**	Health worry	Q4	-0.56**	
	Q6	-0.86**		Q15	-0.74**	
	Q7	-0.82**		Q32	-0.19	
	Interference with activity	Q9	-0.76**	Food avoidance	Q11	-0.45**
		Q10	-0.75**		Q23	-0.55**
		Q13	-0.72**		Q28	-0.59**
		Q16	-0.80**	Social reaction	Q2	-0.60**
Q30		-0.89**	Q14		-0.54**	
Q3		-0.60**	Q17		-0.60**	
Sexual	Q18	-0.78**	Relationships	Q34	-0.79**	
	Q19	-0.60**		Q8	-0.66**	
	Q22	-0.70**		Q24	-0.70**	
	Q27	-0.75**	Body image	Q33	-0.70**	
	Q29	-0.73**		Q5	-0.10	
	Q31	-0.53**		Q21	-0.76**	
	Q12	-0.30*	Q25	-0.61**		
	Q20	-0.47**	Q26	-0.68**		

*p < 0.05, **p < 0.01; Pearson's correlation coefficient between individual items and overall score of the IBS-QOL-J.

Recently, we have translated the Rome II modular questionnaire for IBS and the IBSSI into Japanese and have confirmed reliability and reproducibility in patients with functional bowel disorders (FBD) [22]. Our results in the present study show that the IBS-QOL-J is strongly correlated with the self-rating scales for the overall severity measure. Besides, patients who reported continuous or nearly continuous abdominal pain showed a lower overall score on the IBS-QOL-J than those who did not. On the other hand, our study did not confirm that there are significant differences in the QOL score among subtypes of bowel movement in patients with IBS. These results suggest that IBS patients who have abdominal pain continuously may have more impaired QOL despite predominant stool patterns. Furthermore, patients considered as frequent consulters according to a previous systemic review [29] show lower scores in the IBS-QOL-J. Previous reports on the original IBS-QOL show a significant association between the IBS-QOL and number of visit to physicians for IBS problems [14]. Thus, the findings of the present

study are consistent with those of the original version of the disease-specific QOL measure for IBS.

The mean overall score of the IBS-QOL-J in patients with IBS was similar with that of original version [12] measured in the U.S. (68.2 vs. 63.2 points) despite different diagnostic criteria (Rome II vs. Rome I) and subject population (tertiary care vs. GI clinic plus advertisement). The mean overall score of the IBS-QOL-J in patients with IBS also showed a similar result with that measured by the Korean version of the IBS-QOL in South Korea [21]. Nevertheless, the mean individual scores of body image (80.0 vs. 62.5), health worry (73.1 vs. 59.2), food avoidance (55.3 vs. 43.4) and sexual concerns (89.2 vs. 73.5) on the Japanese version were over 10-point higher [12] (see Table 5).

Our results failed to confirm that the overall IBS-QOL-J score is significantly associated with the individual scores of the abdominal pain severity or pain duration in the

Table 4: Correlations between overall score of the IBS-QOL-J and overall and individual scores of the IBSSI-J

	IBS-QOL-J	
	Correlation	Significance
IBSSI-J		
Overall	-0.36	0.01
Abdominal pain (severity)	-0.21	N.S.
Abdominal pain (duration)	-0.23	N.S.
Abdominal distension	-0.00	N.S.
Bowel movement	-0.32	0.03
Quality of life	-0.47	0.001




Figure 1
 Comparison of the IBS-QOL-J scores between patients who reported continuous or nearly continuous abdominal pain and those who did not. Results were expressed as mean with standard deviation of the overall scores on the IBS-QOL-J. Patients who reported continuous abdominal pain showed a significant lower score than those who did not (**p* < 0.01, Mann-Whitney U test).

IBSSI-J. We do not believe that gastrointestinal (GI) symptoms of the patients in this study were less severe because more than two-thirds demonstrated moderate to severe symptoms on the IBSSI-J according to the severity classification system on the original version [25] (see Table 1). Despite 41 of 49 patients had taken medical treatment for

their GI symptoms including antispasmodic agents and antidepressants, they did not report lower abdominal pain scores compared with the rest of the patients who had not in the present study.

It has been demonstrated that the Japanese subjects are less prone to be accepting of pain behaviors [30] and express their sexual activities to someone [31] compared with people in the Western countries. There was no difference in the individual score of sexual concerns between married and unmarried patients in this study, in fact. When the sexual concerns are assessed in the Japanese patients, it should be taken into account that they may hesitate or avoid expression of such topics even if they have any sexual problems. Although we could not compare differences in these scores directly, cross-cultural difference between the countries (e.g. race, food, belief, social milieu and health-care system) might affect some dimensions of perception for the health-related QOL in patients with IBS.

The IBS-QOL-J appears to be a reliable instrument to assess the disease-specific QOL for IBS in Japanese patients. However, this validation study was cross-sectional, and thus could not investigate responsiveness. Moreover, our sample was relatively small and recruited from only the referred FBD patients. Further validation studies are warranted to investigate reliability and validity on the Japanese version of the IBS-QOL. It is important to assess not only severity of symptoms but also disease-specific QOL when considering the strategy for treatment for IBS since no biological measure is available for assessing IBS. Considering cross-cultural comparisons, these instru-

Table 5: Comparison of the IBS-QOL between Japan and the U.S

	Score (mean ± SD)		
	IBS (Japan)	Other FBD (Japan)	IBS* (U.S.)
Number	30	19	155
Female (%)	18 (60)	9 (47)	138 (89)
Age (yrs)	39 ± 17	37 ± 12	39 ± 12
IBSSI (Overall)	250 ± 95.5 ^a	172 ± 89.8	- ^b
IBS-QOL			
Overall	68.2 ± 19.7	73.6 ± 20.2	63.2 ± 18.5
Dysphoria	61.0 ± 26.8	62.2 ± 28.4	63.1 ± 23.9
Interference with activity	62.3 ± 25.8	72.9 ± 21.9	63.1 ± 22.3
Body image	80.0 ± 18.0	87.5 ± 17.4	62.5 ± 24.3
Health worry	73.1 ± 19.4	80.7 ± 16.7	59.2 ± 24.6
Food avoidance	55.3 ± 27.2	66.2 ± 29.1	43.4 ± 26.7
Social reaction	77.1 ± 18.9	79.9 ± 21.4	69.4 ± 22.9
Sexual concerns	89.2 ± 22.9	87.5 ± 13.2	73.5 ± 27.6
Relationships	72.2 ± 23.0	67.7 ± 29.8	72.3 ± 21.7

*IBS was diagnosed by Rome I criteria, data from Patrick, et al, 1998 (with permission, ref. 12). ^a*p* < 0.01 vs other FBD. ^bIBSSI was not investigated. Higher values indicate better QOL score for the IBS-QOL.

ments are likely to be a valuable tool to investigate the QOL in Japanese patients with IBS.

Additional material

Additional File 1

Japanese version of irritable bowel syndrome quality of life (IBS-QOL-I) instrument.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1751-0759-1-6-S1.pdf>]

Acknowledgements

The authors wish to thank Mr. Jeremy Simmons and Ms. Shigeko Simmons for the back-translation on the instruments. This work was supported by Grant-in-Aids for scientific research from Ministry of Education, Science, Sports and Culture and Ministry of Health, Welfare, and Labor, Japan.

References

- Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG: **U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact.** *Dig Dis Sci* 1993, **38**:1569-1580.
- Locke GR 3rd, Weaver AL, Melton LJ 3rd, Talley NJ: **Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study.** *Am J Gastroenterol* 2004, **99**:350-357.
- Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: **The impact of irritable bowel syndrome on health-related quality of life.** *Gastroenterology* 2000, **119**:654-660.
- Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C: **Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases.** *Clin Ther* 2002, **24**:675-689.
- Drossman DA, Sandler RS, McKee DC, Lovitz AJ: **Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction.** *Gastroenterology* 1982, **83**:529-534.
- Kanazawa M, Endo Y, Whitehead WE, Kano M, Hongo M, Fukudo S: **Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress.** *Dig Dis Sci* 2004, **49**:1046-1053.
- Whitehead WE, Burnett CK, Cook EW 3rd, Taub E: **Impact of irritable bowel syndrome on quality of life.** *Dig Dis Sci* 1996, **41**:2248-2253.
- Ware JE, Sherbourne CD: **The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.** *Med Care* 1992, **30**:473-483.
- Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE: **Psychosocial aspects of the functional gastrointestinal disorders.** In *Rome II The Functional Gastrointestinal Disorders 2nd edition*. Edited by: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. McLean, VA: Degnon Associates; 2000:157-245.
- Guyatt GH, Feeny DH, Patrick DL: **Measuring health-related quality of life.** *Ann Intern Med* 1993, **118**:622-629.
- Drossman DA: **Inflammatory bowel disease.** In *Quality of life and pharmacoeconomics in clinical trials 2nd edition*. Edited by: Spilker B. New York: Raven Press; 1966:925-935.
- Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL: **Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.** *Dig Dis Sci* 1998, **43**:400-411.
- McKenna SP: **A new theoretical approach to the measurement of quality of life.** *Drug Inf J* 1994, **28**:13-18.
- Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, Jia H, Bangdiwala SI: **Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.** *Am J Gastroenterol* 2000, **95**:999-1007.
- Drossman DA, Whitehead WE, Toner BB, Diamant N, Hu YJ, Bangdiwala SI, Jia H: **What determines severity among patients with painful functional bowel disorders?** *Am J Gastroenterol* 2000, **95**:974-980.
- Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ: **Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.** *Pharmacoeconomics* 2002, **20**:455-462.
- Wang W, Pan G, Qian J: **Cognitive therapy for patients with refractory irritable bowel syndrome [in Chinese with English abstract].** *Zhonghua Nei Ke Za Zhi* 2002, **41**:156-159.
- Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmot S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI: **Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.** *Gastroenterology* 2003, **125**:19-31.
- Whitehead WE, Levy RL, Von Korff M, Whitehead WE, Levy RL, Von Korff M, Feld AD, Palsson OS, Turner M, Drossman DA: **The usual medical care for irritable bowel syndrome.** *Aliment Pharmacol Ther* 2004, **20**:1305-1315.
- Blanchard EB, Lackner JM, Gusmano R, Gudleski GD, Sanders K, Keefer L, Krasner S: **Prediction of treatment outcome among patients with irritable bowel syndrome treated with group cognitive therapy.** *Behav Res Ther* 2006, **44**:317-337.
- Park JM, Choi MG, Oh JH, Cho YK, Lee IS, Kim SW, Choi KY, Chung IS: **Cross-cultural validation of irritable bowel syndrome quality of life in Korea.** *Dig Dis Sci* 2006, **51**:1478-1484.
- Shinozaki M, Kanazawa M, Sagami Y, Endo Y, Hongo M, Drossman DA, Whitehead WE, Fukudo S: **Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index.** *J Gastroenterol* 2006, **41**:491-494.
- Drossman DA, Talley NJ, Whitehead WE, Thompson WG, Corazziari E: **Research diagnostic questions for functional gastrointestinal disorders: Rome II Modular Questionnaire: Investigations and Respondent Forms.** In *Rome II The Functional Gastrointestinal Disorders 2nd edition*. Edited by: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. McLean, VA: Degnon Associates; 2000:669-714.
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: **Functional bowel disorders.** *Gastroenterology* 2006, **130**:1480-1491.
- Francis CY, Morris J, Whorwell PJ: **The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.** *Aliment Pharmacol Ther* 1997, **11**:395-402.
- Lembo A, Ameen VZ, Drossman DA: **Irritable bowel syndrome: toward an understanding of severity.** *Clin Gastroenterol Hepatol* 2005, **3**:717-725.
- Hahn BA, Kirchoefer LJ, Fullerton S, Mayer E: **Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.** *Aliment Pharmacol Ther* 1997, **11**:547-552.
- Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW: **Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics.** *Am J Gastroenterol* 2003, **98**:122-127.
- Gill D, Sharpe M: **Frequent consulters in general practice: a systematic review of studies of prevalence, associations and outcome.** *J Psychosom Res* 1999, **47**:115-130.
- Hobara M: **Beliefs about appropriate pain behavior: cross-cultural and sex differences between Japanese and Euro-Americans.** *Eur J Pain* 2005, **9**:389-393.
- Ide M, Fugl-Meyer AR: **Life satisfaction in persons with spinal cord injury: a comparative investigation between Sweden and Japan.** *Spinal Cord* 2001, **39**:387-393.



Research papers

Correlation between alexithymia and hypersensitivity to visceral stimulation in human

Michiko Kano ^{a,b}, Toyohiro Hamaguchi ^a, Masatoshi Itoh ^c,
Kazuhiko Yanai ^d, Shin Fukudo ^{a,*}

^a Behavioral Medicine, Tohoku University School of Medicine, 2-1 Seiryō-cho, Aoba-ku, Sendai 980-8575, Japan

^b Department of Psychosomatic Medicine, Ohta Nishinouchi Hospital, Koriyama, Japan

^c Cyclotron Radioisotope Center, Tohoku University, Sendai, Japan

^d Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan

Received 11 March 2006; received in revised form 23 January 2007; accepted 23 January 2007

Abstract

Empirical studies indicate that alexithymia exacerbates physical illness. However, direct evidence to explain the mechanism of this exacerbation has not been provided. One hypothesis is that alexithymics amplify unpleasant internal signals. In the present study, we investigated how alexithymia influences sensitivity to visceral stimulation in human. In 45 non-clinical healthy subjects (34 males and 11 females), brain processing of visceral sensation induced by colonic distension was examined using $H_2^{15}O$ positron emission tomography (PET). Subjective feeling evaluated on an ordinate scale and neuroendocrine response to stimuli were also measured. The degree of alexithymia was determined using the 20-item of Toronto alexithymia scale (TAS-20), and the correlation between reaction to stimuli and the scores of TAS-20 and its three subscales [difficulty to identify feelings (DIF), difficulty to describe feelings (DDF) and external oriented thinking (EOT)] was evaluated. Greater activation was observed during colonic distension in the pregenual anterior cingulate cortex, right insula and midbrain in the 10 (out of 45) subjects that were identified as alexithymic by TAS-20 scores larger than 61. TAS-20 scores positively correlated with both activity in the right insula and orbital gyrus and adrenaline levels in the blood in response to stimulation. Subjects with high scores of DIF perceived strong pain, urgency for defecation, stress, anxiety, and slight sleepiness. The present study demonstrates that alexithymia is associated with hypersensitivity to visceral stimulation. This finding supports the somatosensory amplification hypothesized in alexithymics and is important to elucidate the influence of alexithymia on brain-gut function, particularly to understand the pathophysiology of FGIDs (functional gastrointestinal disorders).

© 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Keywords: Visceral pain; Alexithymia; Hypersensitivity; PET; Emotional perception

1. Introduction

Alexithymia is a personality construct derived from clinical observations of patients with psychosomatic illness (Sifneos, 1973), and is characterized by the follow-

ing: reduced ability to identify and describe one's feelings, difficulty in distinguishing feelings from the bodily sensations of emotional arousal, impaired symbolization, and a tendency to focus on external events rather than inner experiences (Taylor et al., 1997). High rates of alexithymia have been reported in patients with essential hypertension, myocardial infarction, inflammatory bowel disease (IBD), functional gastrointestinal disorders (FGIDs), chronic pain, somatization, panic

* Corresponding author. Tel./fax: +81 22 717 8214.

E-mail address: sfukudo@mail.tains.tohoku.ac.jp (S. Fukudo).

disorder, eating disorders, and post-traumatic stress disorders (Taylor, 2000). These findings suggest that alexithymia has aversive effects not only on mental health but also on physical health.

Several pathways linking alexithymia to physical illness have been hypothesized at the physiological, behavioral, and cognitive levels (Lumley et al., 1996). One is that affect regulation and elaboration are impaired in alexithymics. In that case, arousal, which can continuously remain active, potentially disturbs the autonomic, pituitary–adrenal, and/or immune systems leading to tissue damage. Alexithymia may also indirectly lead individuals to physical illness by prompting unhealthy behavior, such as smoking, drug abuse, disordered eating, or a sedentary lifestyle. Another hypothesis is that alexithymics amplify unpleasant proprioceptive or external stimulation. Previous studies have shown that the degree of alexithymia correlates with the score of somatosensory amplification and that alexithymics exhibit significantly low tolerance to painful electric stimulation (Nyklicek and Vingerhoets, 2000; Nakao et al., 2002). However, no direct evidence on how alexithymia relates to somatic symptoms or physical illnesses has been provided.

FGIDs are characterized by chronic gastrointestinal symptoms with no biochemical or structural abnormalities detected by routine clinical examination and are therefore distinguished from IBD, which involves discrete inflammation of the gastrointestinal tract (Drossman, 2006). FGIDs highly associated with alexithymia as 66% of patients with FGIDs have been reported to have high alexithymic scores even after the influence of anxiety and depression has been controlled (Porcelli et al., 1999). Patients with FGIDs who do not respond to treatment are more likely to have alexithymia than those who do, making alexithymia a potential predictor of treatment outcome in FGID patients (Porcelli et al., 2003; Porcelli et al., 2004b). FGID symptoms result from deregulation of both intestinal motor and sensory functions, and central nervous system activity, which is mediated by bi-directional circuits between the central and enteric nervous systems; the so-called “brain-gut” axis (Drossman, 2006). Brain-gut function has been investigated using neuroimaging techniques that measure brain response during gut stimulation (Derbyshire, 2003). Using this method to understand the mechanism by which alexithymia may affect brain-gut function would help clarify the pathways that link alexithymia to FGIDs.

The primary aim of the present study was to examine how alexithymia associates with sensitivity to visceral stimulation. In our experiments, brain activity, blood neuroendocrine levels, and subjective perception in response to visceral stimulation induced by a barostat bag inserted into the colon were measured in healthy volunteers.

2. Methods

2.1. Subjects

Forty-five healthy volunteers (34 males and 11 females) participated in this study. All subjects were right-handed and aged 22 ± 2 (mean \pm SD). Each subject underwent a basic evaluation including a medical history review to exclude individuals with organic diseases and was given a physical examination and colonoscopy. None of the subjects had a history of psychiatric or neurological disorders, and none had gastrointestinal symptoms or signs. Subjects were given a description of the study protocol, and their written informed consents were obtained. This study was approved by the Ethics Committee of Tohoku University School of Medicine and was performed in accordance with the policy of the Declaration of Helsinki.

2.2. Assessment of alexithymia

Alexithymia was assessed in each subject using the 20-item of Toronto alexithymia scale (TAS-20), which is the most psychometrically valid measurement of alexithymia (Bagby et al., 1994a,b; Parker et al., 2003; Taylor et al., 2003). TAS-20, which comprises three subscales, i.e. difficulty to identify feelings (DIF), difficulty to describe ones' feelings (DDF), and presence of externally oriented thinking (EOT), is a self-report questionnaire with maximum score of 100 that measures participants' ability to describe and identify feelings, and their tendency to exhibit externally oriented thinking. Participants answer questions on a 5-point scale indicating ‘strongly disagree’ to ‘strongly agree.’ Individuals with a TAS-20 total score of more than 61 are considered alexithymic and those with a score of less than 51 are considered non-alexithymic (Taylor et al., 1997). The Japanese version of the TAS-20 has already been found to be psychometrically valid (Komaki et al., 2003).

2.3. Protocol

On the day before the experiment, subjects were given low residue meals and their colons were cleansed as previously described (Hamaguchi et al., 2004). In the morning of the experiment day, colonoscopy was performed on each subject under X-ray monitoring. A splinting device was inserted into the descending colon and the colonoscope was removed. A catheter with a barostat bag (700 ml in volume) was then inserted into the upper part of the descending colon and the splinting device was removed. Colonic distension stimuli were provided with a computerized barostat pump (Mdetronics Synectics, Shoreview, MN, USA), which inflated the bag at a rate of 38 ml/s. First each subject underwent a baseline PET scan without bag stimulation. Thereafter, the colon was stimulated with a bag pressure of 0, 20, and 40 mmHg for 80 s. The intensity of each stimulus was randomly chosen to avoid stimulation order effect, and the time interval between two stimuli was 15 min.

2.4. PET scan acquisition

Scans of the distribution of H_2^{15}O were obtained using an SET-2400W PET scanner (Shimadzu, Japan) operated at high sensitivity three-dimensional mode with average axial

resolution of 4.5 mm at maximum strength and sensitivity for a 20-cm cylindrical phantom of 48.6 kcps/kBq/ml (Fujiwara et al., 1997). For each scan, the subject received approximately 5 mCi (185 MBq) of $H_2^{15}O$ intravenously through the antecubital vein and underwent colonic distension during measurement of rCBF. Scans were started about 10 s after the beginning of colonic distension, at which both radioactivity peak and peak pressure of the bag reached simultaneously a plateau. PET scanning room was darkened and the subjects, while awake, were instructed to keep their eyes closed for the whole period of the scan (70 s).

2.5. Subjective perception of stimulation

After each visceral stimulation, the subjects were asked to report the following seven items of visceral sensation or emotion: abdominal discomfort, abdominal distension, abdominal pain, urgency for defecation, perceived stress, sleepiness, and anxiety. Each sensation was evaluated on an ordinate scale from 0 (no sensation) to 10 (maximal sensation) as previously described (Hamaguchi et al., 2004). Abdominal distension was characterized by a swollen abdomen due to colon pressure, while abdominal discomfort was characterized as any other uncomfortable feeling in the abdomen. Abdominal pain was defined as any soreness in the abdomen and urgency for defecation was defined as a sudden compelling urge to defecate. To evaluate responses to stimulation, differences in the value of each ordinate scale between baseline and stimulation with 40, 20, and 0 mmHg were used for analysis.

2.6. Biochemical assays

A plastic catheter was inserted into the left forearm vein of each subject and saline was infused at a speed of 1.6 ml/min. Blood samples were taken through the catheter after each PET scan (baseline, 0, 20, and 40 mmHg) and immediately centrifuged at 3000 rpm at 4 °C for 5 min. The supernatant was aspirated and stored at –20 °C until assay. Levels of plasma ACTH and serum cortisol were measured by standard radio-immunoassay. Levels of noradrenaline and adrenaline in the plasma were determined with high-performance liquid chromatography and electrochemical detection after batch alumina extraction. To evaluate responses to stimulation, the ratio of value after stimulation with 40, 20, and 0 mmHg/value at baseline in each blood sample was used for analysis.

2.7. Statistical analysis

Statistical parametric mapping software (SPM2, Wellcome department of Cognitive Neurology, London, UK) was used for PET images realignment, normalization, smoothing, and to create statistical maps of significant rCBF changes (Friston et al., 1995a; Friston et al., 1995b). All rCBF images were stereotaxically normalized into the standard space defined by Talairach and Tournoux (1988) using an rCBF template image supplied with SPM2. The normalized images were smoothed using a $12 \times 12 \times 12$ -mm Gaussian filter, and the values of rCBF were expressed in $ml\ dl^{-1}\ min^{-1}$, adjusted for individual global CBF values using the ANCOVA, and scaled to the mean of 50. Contribution of each parameter of interest to changes in rCBF was estimated by SPM2 according to the gen-

eral linear model at voxel level. Estimates were made using linear compounds of contrasts, and the resulting set of voxel values constituted a parametric map for each contrast. To examine whether specific brain regions correlate with alexithymia, we performed a correlation analysis between rCBF changes at stimulation with the pressure of 40, 20, 0 mmHg and individual TAS-20 scores for all 45 subjects. Additionally, a conjunction analysis was performed to assess differences between alexithymic and non-alexithymic subjects in cerebral regional activation at stimulation with the pressure of 40 mmHg as compared no stimulation (baseline). Conjunction analysis can reveal brain areas with significant main effect of two contrasts (Price and Friston, 1997). In our analysis, alexithymia_{40mmHg-baseline} and non-alexithymia_{40mmHg-baseline} were subtracted. Voxels were considered statistically significant at a threshold of $p < 0.001$ (uncorrected). Correlation between the difference in the value of each ordinate scale, TAS-20 score, and TAS-20 subscale values was evaluated by the Pearson's correlation method for all 45 subjects. Similarly, correlation between the difference in the ratio value in each blood sample, TAS-20 score, and TAS-20 subscale value was evaluated by the Pearson's correlation method for all 45 subjects.

3. Results

3.1. TAS-20 score

The averaged TAS-20 score of the 45 volunteers was 47.8 ± 11 (mean \pm SD), while the averaged scores for DIF, DDF, and EOT subscales were 14.0 ± 7.2 , 14.0 ± 5.0 , and 19.5 ± 3.6 (mean \pm SD), respectively. Among the 45 subjects, 10 individuals (5 males and 5 females) with TAS-20 scores of more than 61 (61–67) were considered alexithymic and 28 individuals (22 males and 6 females) with TAS-20 scores of less than 51 (26–50) were considered non-alexithymic according to cut-off criteria (Taylor et al., 1997). For reference, an approximate 8–10% alexithymia prevalence has been reported in normal population (Taylor, 2000). Actually, in our previous study, the averaged TAS-20 score of 247 student volunteers was 46.5 ± 8.5 (mean \pm SD) (Kano et al., 2003). In addition, in a sample of Finish general population ($n = 2018$) between the age of 25 and 64 years, the prevalence of alexithymia was 12.8% in men and 8.2% in women and the averaged TAS-20 score was 44.1 ± 11.8 (mean \pm SD) (Honkalampi et al., 2000).

3.2. Correlation between alexithymia and subjective perception following visceral stimulation

The correlation between individual TAS-20 and TAS-20 subscale scores, and subjective perception of colonic stimulation is shown in Table 1 and Fig. 1. At stimulation with the pressure of 40 mmHg, TAS-20 score significantly correlated with abdominal distension ($r = 0.3$, $p < 0.05$) and anxiety ($r = 0.3$, $p < 0.05$), while the score of DIF (difficulty to identify feelings) correlated with abdominal distension ($r = 0.27$, $p < 0.05$), abdominal pain ($r = 0.34$,

Table 1

Correlation (*r*) between individual TAS-20 and TAS-20 subscale scores and subjective visceral perception (abdominal discomfort, abdominal distension, abdominal pain, urgency for defecation, perceived stress, sleepiness, and anxiety) to colonic stimulation with (a) 40, (b) 20, and (c) 0 mmHg

	Discomfort	Distension	Pain	Urgency	Stress	Sleepiness	Anxiety
(a) 40 mmHg							
TAS20	0.05	0.3*	0.21	0.15	0.20	-0.10	0.3*
DIF	0.20	0.27*	0.34*	0.31*	0.3*	-0.3*	0.42**
DDF	-0.13	0.08	0.03	-0.02	0.06	0.18	0.14
EOT	-0.06	0.11	-0.03	-0.05	0.03	-0.04	-0.05
(b) 20 mmHg							
TAS20	0.01	0.11	-0.03	-0.19	0.02	-0.04	0.13
DIF	0.14	0.24	0.13	-0.13	0.24	-0.29	0.27
DDF	-0.04	0.02	-0.16	-0.13	-0.01	0.00	0.03
EOT	-0.21	-0.17	-0.16	-0.11	-0.26	0.39**	-0.15
(c) 0 mmHg							
TAS20	0.04	-0.01	-0.06	-0.18	-0.14	0.06	0.09
DIF	0.12	0.15	-0.02	-0.20	-0.10	-0.11	0.09
DDF	0.16	0.74	0.02	-0.08	-0.08	-0.07	0.03
EOT	-0.30*	-0.38**	-0.2	-0.09	-0.1	0.47**	0.05

Significance, **p* < 0.05; ***p* < 0.01.




Fig. 1. Plot of the relationship between individual TAS-20 and TAS-20 subscale scores, and subjective visceral perception (abdominal discomfort, abdominal distension, abdominal pain, urgency for defecation, perceived stress, sleepiness, and anxiety) to colonic stimulation with (a) 40, (b) 20, and (c) 0 mmHg.




Fig. 1 (continued)

$p < 0.05$), urgency for defecation ($r = 0.31$, $p < 0.05$), perceived stress ($r = 0.3$, $p < 0.05$), sleepiness ($r = -0.3$, $p < 0.05$), and anxiety ($r = 0.28$, $p < 0.005$). The scores of DDF (difficulty to describe feelings) and EOT (externally oriented thinking) did not correlate with any subjective perception. At stimulation with the pressure of 20 mmHg, the scores of TAS-20, DIF, and DDF did not correlate with any visceral perception. However, the score of EOT correlated with sleepiness ($r = 0.39$, $p < 0.01$). At sham stimulation (0 mmHg), the scores of TAS-20, DIF, and DDF did not correlate with any subjective feeling, while the score of EOT correlated with abdominal discomfort ($r = -0.3$, $p < 0.05$), abdominal distension ($r = -0.38$, $p < 0.01$), and sleepiness ($r = 0.47$, $p < 0.01$).

3.3. Correlation between alexithymia and changes in blood neuroendocrine levels in response to visceral stimulation

The correlation between the degree of alexithymia and changes in blood neuroendocrine levels in response to colonic stimulation with the pressure of 40 mmHg is

shown in Table 2. TAS-20 score positively correlated with blood level of adrenaline ($r = 0.29$, $p < 0.05$), while the score of DIF positively correlated with blood levels of ACTH ($r = 0.33$, $p < 0.05$) and adrenaline ($r = 0.39$, $p < 0.01$). In contrast, the score of EOT negatively correlated with blood levels of ACTH ($r = -0.31$, $p < 0.05$) and adrenaline ($r = -0.27$, $p < 0.05$). There was no correlation between the score of TAS-20, DIF, DDF, or EOT and change in blood neuroendocrine levels in response to colonic stimulation with the pressure of 0 and 20 mmHg.

3.4. Correlation between alexithymia and rCBF following visceral stimulation

At stimulation with the pressure of 40 mmHg, TAS-20 score positively correlated with rCBF in the orbital gyrus, insula, frontal gyrus, superior temporal gyrus, precentral gyrus, and cerebellum (Fig. 2 and Table 3). On the other hand, TAS-20 score negatively correlated with rCBF in the superior parietal lobe, cuneus, precuneus, middle frontal gyrus, and cerebellum (Fig. 3). The score of DIF positively correlated with rCBF in





Fig. 1 (continued)

the orbital gyrus, insula, frontal gyrus, and cerebellum. Brain areas that negatively correlated with the score of DIF were: the precuneus, cuneus, and cerebellum. The score of DDF positively correlated with rCBF in the orbital gyrus, inferior parietal gyrus, frontal gyrus, and insula, and negatively correlated with the parietal and occipital gyrus and precuneus. Although TAS-20 score, the score of DIF, and the score of DDF correlated either positively or negatively with rCBF in similar brain areas (e.g. orbital gyrus and insula) areas that correlated with the score of EOT were distinct. The score of EOT posi-

tively correlated with rCBF in the middle and temporal gyrus, precuneus, inferior temporal gyrus, postcentral gyrus, and supramarginal gyrus, and negatively corre-

(1) Orbital gyrus



(2) insula




Fig. 2. A statistical parametric map (SPM) showing the bilateral orbital gyrus and the right insula where rCBF positively correlated with TAS-20 score during colonic stimulation with a bag pressure of 40 mmHg ($p < 0.001$, uncorrected).

Table 2

Correlation between individual TAS-20 and TAS-20 subscale scores and changes in blood neuroendocrine levels in response to colonic stimulation with 40 mmHg

	Cortisol	ACTH	Adrenaline	Noradrenaline
TAS20	0.11	0.14	0.29*	0.09
DIF	0.06	0.33*	0.39**	0.16
DDF	0.11	0.14	0.29	0.09
EOT	-0.07	-0.31*	-0.27*	-0.11

ACTH, adrenocorticotropic hormone; Significance, * $p < 0.05$; ** $p < 0.01$.

Table 3

Coordinates and Z-scores for brain areas that positively or correlated with TAS-20 score and the scores of DIF, DDF and EOT during colonic stimulation with 40 mmHg ($p < 0.001$, uncorrected)

Region (putative Brodmann's area)	Cluster size	Z-score	Talairach coordinates		
			x	y	z
<i>TAS 20 positive correlation</i>					
Orbital gyrus (47)	99	4.29	-12	26	-22
Insula (13)	73	4.26	44	0	4
Middle frontal gyrus (8)	50	4.19	44	28	40
Middle frontal gyrus (46)	78	3.83	54	36	26
Orbital gyrus (11/47)	168	3.66	20	30	-28
Cerebellum	99	3.62	-28	-70	-50
Superior temporal gyrus	26	3.61	-62	-26	14
Precentral gyrus (6)	24	3.56	62	-14	38
Cerebellum	31	3.48	28	-76	-50
Superior frontal gyrus (11)	41	3.46	-10	50	-24
<i>TAS 20 negative correlation</i>					
Cerebellum	233	4.52	-40	-78	-16
Cerebellum	403	4.19	42	-74	-2
Superior parietal lobe (7)	33	3.87	32	-50	62
Cuneus (7)	65	3.71	-16	-74	32
Precuneus (7)	68	3.65	-2	-68	58
Middle frontal gyrus (6)	41	3.45	-28	-6	56
Precuneus (7)	28	3.42	-8	-48	46
<i>DIF positive correlation</i>					
Orbital gyrus (11/47)	52	4.06	16	38	-24
Cerebellum	66	4.04	14	-82	-40
Insula (13)	235	4.00	44	-4	6
Cerebellum	64	3.71	-22	-76	-50
Superior frontal gyrus (10)	57	3.64	-28	44	20
Insula (13)	26	3.52	-54	2	4
<i>DIF negative correlation</i>					
Precuneus (7)	97	3.72	0	-70	60
Cuneus (7)	51	3.65	-16	-72	32
Cerebellum	27	3.47	-36	-78	-16
<i>DDF positive correlation</i>					
Orbital gyrus (47)	168	4.37	-12	28	-24
Inferior parietal gyrus (39)	80	3.83	-53	-60	42
Frontal lobe sub-gyrus	37	3.79	-28	42	0
Middle frontal gyrus (8)	42	3.72	46	26	42
Supramarginal gyrus (39/40)	79	3.66	-62	-50	28
Middle frontal gyrus (46)	29	3.53	56	36	28
Insula (13)	22	3.40	30	12	6
<i>DDF negative correlation</i>					
Superior parietal lobe (7)	75	4.25	32	-48	62
Middle temporal gyrus (39)	145	3.84	50	-60	6
Inferior occipital gyrus (18)	73	3.81	-38	-80	-14
Precuneus (7)	48	3.64	-16	-56	52
Middle occipital gyrus (19)	48	3.54	24	-92	16
Inferior temporal gyrus (19)	31	3.54	42	-72	-2
Superior parietal lobe (7)	39	3.41	-6	-66	56
Middle occipital gyrus (19)	3.4	3.4	-18	-100	8
<i>EOT positive correlation</i>					
Middle temporal gyrus (22)	592	3.99	54	-38	4
Cerebellum	213	3.98	36	-86	-30
Inferior temporal gyrus (20)	80	3.91	-60	-16	-28
Precuneus (7)	37	3.74	12	-76	42
Cerebellum declive	30	3.62	-52	-52	-20
Inferior temporal gyrus (21)	43	3.51	-54	-54	-4
Inferior temporal gyrus (21)	131	3.51	60	-4	-14

Table 3 (continued)

Region (putative Brodmann's area)	Cluster size	Z-score	Talairach coordinates		
			x	y	z
Postcentral gyrus (43)	75	3.43	53	-12	18
Supramarginal gyrus (40)	66	3.31	-58	-54	24
<i>EOT negative correlation</i>					
Middle frontal gyrus (6)	67	3.35	-2	-26	58

lated with rCBF in the middle frontal gyrus. At stimulation with 20 and 0 mmHg, no correlation between the score of TAS-20 and rCBF was observed in any brain area.

3.5. Differences in response to visceral stimulation between alexithymics and non-alexithymics

Differences between alexithymics and non-alexithymics in response to visceral stimulation with the pressure of 40 mmHg are listed in Table 4. Areas of the brain where rCBF was higher in the alexithymics than in the non-alexithymics were: the right insula, middle frontal gyrus, midbrain, pregenual anterior cingulate gyrus, superior temporal gyrus, and postcentral gyrus (Fig. 4). In contrast, areas of the brain where the alexithymics had lower rCBF than the non-alexithymics were: the inferior frontal lobe, occipital lobe, inferior parietal lobe, cerebellum, and cuneus.


4. Discussion

The present study demonstrates that alexithymia is associated with hypersensitivity to visceral stimulation induced by colonic distension. The salient results were as follows: (1) TAS-20 score positively correlated with activation of brain areas, such as the insula and orbital

gyrus. Also, visceral stimulation induced more activation in the insula, pregenual anterior cingulate cortex, and brainstem of the alexithymics than in those of the non-alexithymics. (2) Blood levels of adrenaline in response to colonic stimulation with 40 mmHg positively correlated with TAS-20 score. (3) The more alexithymic subjects were, the more anxiety for visceral stimulation they expressed. Especially, subjects with high score of DIF reported strong pain, urgency for defecation and stress, and less sleepiness than the other subjects. Although these observations may suggest an association between alexithymia and hypersensitivity to visceral stimulation, they need to be interpreted conservatively as it is unclear whether alexithymia causes or results from these effects.

Visceral stimulation, especially by colonic distension, has been reported to elicit activation of various brain areas including, the anterior prefrontal, primary and secondary sensory, perigenual and ventral cingulate, supplementary motor areas, orbitofrontal and insular cortices, thalamus, midbrain, and/or anterior cerebellum (Silverman et al., 1997; Berman et al., 2000; Naliboff et al., 2001; Derbyshire, 2003). In addition, it has been shown that a specialized spinothalamic tract conveys interoceptive sensory information to the cortex, enabling a detailed dynamic representation of particular internal bodily states and that mapping of each interoceptive state occurs within

(1) Right and left occipital lobe



(2) precuneus



Fig. 3. A statistical parametric map (SPM) showing the bilateral occipital lobe and the precuneus where rCBF negatively correlated with TAS-20 score during colonic stimulation with a bag pressure of 40 mmHg ($p < 0.001$, uncorrected).

Anterior cingulate cortex, midbrain, and right insula




Fig. 4. A statistical parametric map (SPM) showing the pregenual anterior cingulate cortex, midbrain, and right insula where rCBF was higher in the alexithymic subjects than in the non-alexithymics during colonic distension with a bag pressure of 40 mmHg ($p < 0.001$, uncorrected).

Table 4

Coordinates and Z-scores for areas where rCBF was higher or lower in the alexithymics than in the non-alexithymics in response to colonic distension with a bag pressure of 40 mmHg ($p < 0.001$, uncorrected)

Region (putative Brodmann's area)	Cluster size	Z-score	Talairach coordinates		
			x	y	z
<i>Alexithymics > non-alexithymics (0 < 40 mmHg)</i>					
Insula (13)	78	4.05	38	-16	16
Middle frontal gyrus (6)	50	3.93	22	28	60
Midbrain	157	3.83	2	-34	-16
Cingulate gyrus (32)	40	3.69	4	42	14
Superior temporal gyrus (22)	36	3.62	44	-40	18
Postcentral gyrus (3)	22	3.47	56	-16	20
<i>Alexithymics < non-alexithymics (0 < 40 mmHg)</i>					
Inferior frontal lobe (45)	130	4.07	-40	-78	-16
Occipital lobe (18)	83	3.96	-36	-92	-16
Inferior parietal lobe (40)	52	3.86	36	-42	44
Parietal lobe (40)	40	3.57	-56	-28	44
Cerebellum	25	3.50	36	-52	-34
Cuneus (18)	23	3.32	-8	-84	14

the orbitofrontal and right insula cortices, which represent the neuroanatomical endpoint of the lamina I interoceptive system (Craig, 2002; Critchley, 2004; Critchley et al., 2004). A recent study has shown that in the large cingulate cortex, the pregenual ACC responded to visceral stimulation and was associated with perception of secondary pain, which is characterized by greater unpleasantness (Vogt, 2005). Electrical stimulation of the insula has been reported to elicit changes in blood pressure, heart rate, respiration, gastric motility, peristaltic activity, salivation, and adrenaline secretion (Neafsey et al., 1993). Moreover, the orbitofrontal cortex has been shown to receive robust sensory input and to act as an internal environmental integrator that coordinates behavioral, autonomic, and endocrine responses (Barbas, 2000). The brainstem, on the other hand, is known to control ascending nociceptive input and nuclei such as the rostral ventromedial medulla and periaqueductal gray (PAG), which are able to both inhibit and facilitate nociceptive responses. Particularly, activation of the right PAG has been reported to correlate with anxiety during visceral stimulation but not somatic stimulation (Dunckley et al., 2005). Therefore, it may be assumed that activation of brain areas associated with alexithymia supports afferent representation of bodily states, and efferent autonomic and endocrine responses that accompany it. In this respect, our results indicate that alexithymics may be more aroused by interoception of unpleasant feeling than non-alexithymics thereby displaying more autonomic responses. The results of this study also support the somatosensory amplification hypothesis on alexithymia and could be used to confirm not only the results of clinical reports showing that alexithymia is associated with pain sensitivity in several chronic pain samples (Lumley et al., 1996; Lumley et al., 2002; Glaros and Lumley, 2005; Lumley et al., 2005), but also the occurrence of gastro-

intestinal symptoms in patients with no reasonable organic abnormalities (Porcelli et al., 1999; Porcelli et al., 2003; Porcelli et al., 2004a,b; van Kerkhoven et al., 2006).

Prior brain studies on alexithymia have focused on its disturbance of emotional processing, based on the hypothesis that people with alexithymia have a deficit in the conscious awareness of emotion (Lane et al., 1997). Anatomically, a significant positive correlation has been reported between the size of the right anterior cingulate gyrus and alexithymia (Gündel et al., 2004). In addition, fMRI studies have shown different activity in the anterior cingulate and the mediofrontal during emotional stimuli processing (Berthoz et al., 2002) and reduced activation of the posterior cingulate cortex during imagination of happy events (Mantani et al., 2005). Accordingly, our previous PET study has revealed reduced activation of the right hemisphere when viewing facial expressions, particularly, low activation of the right dorsal ACC and insula was observed in response to angry faces than to neutral faces (Kano et al., 2003). These findings, which are based on emotion-inducing pictures or recall of emotional events, correspond to features of alexithymia that indicate deficit in cognitive processing of emotion. On the other hand, the present study demonstrates that individuals with high alexithymia were more emotionally distressed and displayed excessive arousal to visceral sensation. Therefore, subjects with alexithymia might be less aware of affective stimuli at the cognitive level but highly aroused by affective stimuli at the physiological level.

From the point of view of cognitive-developmental model of emotional awareness (Lane and Schwartz, 1987), the problem of alexithymia has been posited as deficient development in the cognitive mature stage, which allows some rudimentary form of emotional experiences like awareness of bodily sensations (Lane et al.,

1997; Taylor et al., 1997; Lane et al., 2000; Lane, 2000). Our results may represent intensive responses in an undeveloped form of alexithymia, probably associated with deficit in cognitive emotional processing. Further research is needed to clarify this aspect of alexithymia. Nevertheless in this study, the scores of TAS-20 negatively correlated with rCBF changes in the cuneus and precuneus. The cuneus and precuneus are principal areas involved in conscious recall of memory-related imagery (Fletcher et al., 1995) and may participate in representation of polymodal imagery associated with successful memory retrieval (Maddock et al., 2001), namely these brain areas play a specific role in higher-order cognitive functions (Cavanna and Trimble, 2006). Therefore, deactivation in the cuneus and precuneus in alexithymic subjects during visceral stimulation might be associated with deficits in cognitive processing of emotion. Although contradictory data as to the association between somatosensory amplification and alexithymia have been reported (de Zwaan et al., 1996; Jackson et al., 2002), analysis using TAS-20 subscales indicates that the scores of DIF and DDF, but not that of EOT, are associated with the score of somatosensory amplification scale (SSAS) (Nakao et al., 2002). High scores of DIF were particularly effective in predicting “somatization” scales in 254 psychiatric patients, whereas the scores of DDF and EOT gave no specific indication (Grabe et al., 2004). In several pain studies, DIF and/or DDF scores but not EOT score were associated with sensitivity to pain (Lumley et al., 2002; Glaros and Lumley, 2005; Lumley et al., 2005). Our results are in line with these findings, indicating that among the alexithymic features measured by TAS-20, DIF may be associated with the increased responses.

From the results of previous studies showing that alexithymia was associated with gastrointestinal symptoms with no relation to endoscopic findings in 1141 patients (van Kerkhoven et al., 2006) and that even after controlling the influence of co-morbidity of psychiatric disorders, high rate of alexithymia remained in FGID patients (Porcelli et al., 1999; Porcelli et al., 2004a), the alexithymia construct itself is not something that can be ignored to study FGIDs. Our results revealed the connection between alexithymia and hypersensitivity to visceral stimulation using brain activation, neuroendocrine response, and subjective perception, which are regarded as primary mechanisms of symptom development in FGIDs (Delvaux, 2002; Mertz, 2002; Chang, 2005). We believe that understanding the influence of alexithymia and cognitive emotional processing on brain-gut function would be useful to elucidate the pathophysiology of FGIDs.

This study shed light on the correlation between alexithymia and hypersensitivity to visceral stimulation, however, it has some limitations. Although TAS-20 is the most psychometrically valid measurement of alexi-

thymia, it has been pointed out that there is an overlap between the TAS-20, measures of negative affect, and limitation as a self-report questionnaire (Lane et al., 1997; Subic-Wrana et al., 2005). Future study will be necessary to determine alexithymia tendency by multi-methods including a structured interview, which has been proposed recently (Bagby et al., 2006). Previous studies demonstrated that TAS-20 score in men, but not in women, is associated with the size of ACC (Gündel et al., 2004) and neuroendocrine response (Spitzer et al., 2005), and that there are gender differences for FGID patients in brain activation to rectal distension (Berman et al., 2000; Naliboff et al., 2003; Mayer et al., 2004). The sample size in this study was too small to elucidate the gender differences. Moreover, we adapted a bag pressure of 40 mmHg as a painful visceral stimulation based on previous evidence (Bouin et al., 2002; Hamaguchi et al., 2004), although there are objections that distension with 45–60 mmHg is necessary to produce pain (Naliboff et al., 2003). These discrepancies need to be addressed in future studies with larger sample size.

In conclusion, the present study demonstrates that alexithymia is associated with hypersensitivity to visceral colonic stimulation. Our results show a positive correlation between TAS-20, and (1) activation of specific brain areas; (2) changes in blood neuroendocrine levels; and (3) subjective perception. These results support the somatosensory amplification hypothesis on alexithymia and could be one of the key mechanisms to explain the link between alexithymia and physical illness, especially FGIDs.

Acknowledgements

This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology, and the Ministry of Health, Welfare, and Labor, Japan. The authors appreciate the technical assistance of Mr. Miyake, Y. Ishikawa, and S. Watanuki in PET studies.

References

- Bagby RM, Paker JDA, Talor GJ. The twenty-item Toronto Alexithymia Scale I. Item selection and cross-validation of the factor structure. *J Psychosom Res* 1994a;38:33–40.
- Bagby RM, Talor GJ, Paker JDA. The twenty-item Toronto Alexithymia Scale II. Convergent, discriminant, and concurrent validity. *J Psychosom Res* 1994b;38:23–32.
- Bagby RM, Taylor GJ, Parker JD, Dickens SE. The development of the Toronto Structured Interview for Alexithymia: item selection, factor structure, reliability and concurrent validity. *Psychother Psychosom* 2006;75:25–39.
- Barbas H. Proceeding of the human cerebral cortex: from gene to structure and function. *Brain Res Bull* 2000;52:319–30.

- Berman S, Munakata J, Naliboff BD, Chang L, Mandelkern M, Silverman D, et al. Gender differences in regional brain response to visceral pressure in IBS patients. *Eur J Pain* 2000;4:157–72.
- Berthoz S, Artiges E, Van De Moortele PF, Poline JB, Rouquette S, Consoli SM, et al. Effect of impaired recognition and expression of emotions on frontocingulate cortices: an fMRI study of men with alexithymia. *Am J Psychiatry* 2002;159:961–7.
- Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganier M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. *Gastroenterology* 2002;122:1771–7.
- Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. *Brain* 2006;129:564–83.
- Chang L. Brain responses to visceral and somatic stimuli in irritable bowel syndrome: a central nervous system disorder? *Gastroenterol Clin North Am* 2005;34:271–9.
- Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. *Nat Rev Neurosci* 2002;3:655–66.
- Critchley HD. The human cortex responds to an interoceptive challenge. *Proc Natl Acad Sci USA* 2004;27:6333–4.
- Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ. Neural systems supporting interoceptive awareness. *Nat Neurosci* 2004;7:189–95.
- Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. *Gut* 2002;51:i67–71.
- Derbyshire SW. A systematic review of neuroimaging data during visceral stimulation. *Am J Gastroenterol* 2003;98:12–20.
- de Zwaan M, Biener D, Bach M, Wiesnagrotzki S, Stacher G. Pain sensitivity, alexithymia, and depression in patients with eating disorders: are they related? *J Psychosom Res* 1996;41:65–70.
- Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006;130:1377–90.
- Dunckley P, Wise RG, Fairhurst M, Hobden P, Aziz Q, Chang L, et al. A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. *J Neurosci* 2005;25:7333–41.
- Fletcher PC, Frith CD, Baker SC, Shallice T, Frackowiak RSJ, Dolan RJ. mind's eye? precuneus activation in memory-related imagery. *Neuroimage* 1995;2:195–200.
- Friston K, Ashburner J, Frith CD, Poline J-B, Frith C, Frackowiak RSJ. Spatial registration and normalization of images. *Hum Brain Mapp* 1995a;2:165–89.
- Friston K, Holmes AP, Worsley KJ, Poline J-B, Frith CD, Frackowiak RSJ. Statistical maps in functional imaging: a general linear approach. *Hum Brain Mapp* 1995b;2:189–210.
- Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. *Ann Nucl Med* 1997;11:307–13.
- Glaros AG, Lumley MA. Alexithymia and pain in temporomandibular disorder. *J Psychosom Res* 2005;59:85–8.
- Grabe HJ, Spitzer C, Freyberger HJ. Alexithymia and personality in relation to dimensions of psychopathology. *Am J Psychiatry* 2004;161:1299–301.
- Gündel H, Lopez-Sala A, Ceballos-Baumann AO, Deus J, Cardoner N, Marten-Mittag B, et al. Alexithymia correlates with the size of the right anterior cingulate. *Psychosom Med* 2004;66:132–40.
- Hamaguchi T, Kano M, Rikimaru H, Kanazawa M, Itoh M, Yanai K, et al. Brain activity during distention of the descending colon in humans. *Neurogastroenterol Motil* 2004;16:199–309.
- Honkalampi K, Hintikka J, Tanskanen A, Lehtonen J, Viinamaki H. Depression is strongly associated with alexithymia in the general population. *J Psychosom Res* 2000;48:99–104.
- Jackson T, Nagasaka T, Fritch A, Gunderson J. Alexithymia is not related to tolerance for cold pressor pain. *Percept Mot Skills* 2002;94:487–8.
- Kano M, Fukudo S, Gyoba J, Kamachi M, Tagawa M, Mochizuki H, et al. Specific brain processing of facial expressions in people with alexithymia: an H₂¹⁵O-PET study. *Brain* 2003;126:1474–84.
- Komaki G, Maeda M, Arimura T, Nakata A, Shinoda H, Ogata I. The reliability and factorial validity of the Japanese version of the 20-item Toronto Alexithymia Scale (TAS-20). *Jpn J Psychosom Med* 2003;43:839–46.
- Lane RD. Neural correlates of conscious emotional experience. In: Lane RD, Nadel L, editors. *Cognitive neuroscience of emotion*. New York: Oxford University Press; 2000. p. 345–70.
- Lane RD, Schwartz GE. Levels of emotional awareness: a cognitive-developmental theory and its application to psychopathology. *Am J Psychiatry* 1987;144:1434–9.
- Lane RD, Ahern GL, Schwartz GE, Kaszniak AW. Is alexithymia the emotional equivalent of blindsight? *Biol Psychiatry* 1997;42:834–44.
- Lane RD, Sechrest L, Riedel R, Shapiro DE, Kaszniak AW. Pervasive emotion recognition deficit common to alexithymia and the repressive coping style. *Psychosom Med* 2000;62:492–501.
- Lumley MA, Stettner L, Wehmer F. How are alexithymia and physical illness linked? A review and critique of pathways. *J Psychosom Res* 1996;41:505–18.
- Lumley MA, Smith JA, Longo DJ. The relationship of alexithymia to pain severity and impairment among patients with chronic myofascial pain: comparisons with self-efficacy, catastrophizing, and depression. *J Psychosom Res* 2002;53:823–30.
- Lumley MA, Radcliffe AM, Macklem DJ, Mosley-Williams A, Leisen JC, Huffman JL, et al. Alexithymia and pain in three chronic pain samples: comparing Caucasians and African Americans. *Pain Med* 2005;6:251–61.
- Maddock RJ, arrett AS, Buonocore MH. Remembering familiar people: the posterior cingulate cortex and autobiographical memory retrieval. *Neuroscience* 2001;104:667–76.
- Mantani T, Okamoto Y, Shirao N, Okada G, Yamawaki S. Reduced activation of posterior cingulate cortex during imagery in subjects with high degrees of alexithymia: a functional magnetic resonance imaging study. *Biol Psychiatry* 2005;57:982–90.
- Mayer EA, Berman S, Chang L, Naliboff BD. Sex-based differences in gastrointestinal pain. *Eur J Pain* 2004;8:451–63.
- Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. *Gut* 2002;51:i29–33.
- Nakao M, Barsky AJ, Kumano H, Kuboki T. Relationship between somatosensory amplification and alexithymia in a Japanese psychosomatic clinic. *Psychosomatics* 2002;43:55–60.
- Naliboff BD, Derbyshire SW, Munakata J, Berman S, Mandelkern M, Chang L, et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. *Psychosom Med* 2001;63:365–75.
- Naliboff BD, Berman S, Chang L, Derbyshire SW, Suyenobu B, Vogt BA, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. *Gastroenterology* 2003;124:1738–47.
- Neafsey EJ, Terreberry RR, Hurley KM, Ruit KG, Frysztak RJ. Anterior cingulate cortex in rodents: connections, visceral control functions, and implications for emotion. In: Vogt BA, Gabriel M, editors. *Neurobiology of cingulate cortex and limbic thalamus: a comprehensive handbook*. Boston: Birkhauser; 1993. p. 206–23.
- Nyklicek I, Vingerhoets AJ. Alexithymia is associated with low tolerance to experimental painful stimulation. *Pain* 2000;85:471–5.
- Parker JD, Taylor GJ, Bagby RM. The 20-Item Toronto Alexithymia Scale. III. Reliability and factorial validity in a community population. *J Psychosom Res* 2003;55:269–75.
- Porcelli P, Taylor GJ, Bagby RM, De Carne M. Alexithymia and functional gastrointestinal disorders. A comparison with inflammatory bowel disease. *Psychother Psychosom* 1999;68:263–9.
- Porcelli P, Bagby RM, Taylor GJ, De Carne M, Leandro G, Todarello O. Alexithymia as predictor of treatment outcome in patients with

- functional gastrointestinal disorders. *Psychosom Med* 2003;65:911–8.
- Porcelli P, Affatati V, Bellomo A, De Carne M, Todarello O, Taylor GJ. Alexithymia and psychopathology in patients with psychiatric and functional gastrointestinal disorders. *Psychother Psychosom* 2004a;73:84–91.
- Porcelli P, De Carne M, Todarello O. Prediction of treatment outcome of patients with functional gastrointestinal disorders by the diagnostic criteria for psychosomatic research. *Psychother Psychosom* 2004b;73:166–73.
- Price CJ, Friston KJ. Cognitive conjunction: a new approach to brain activation experiments. *Neuroimage* 1997;5:264–70.
- Sifneos PE. The prevalence of 'alexithymic' characteristic mechanisms in psychosomatic patients. *Psychotherapy and Psychosomatics* 1973;21:133–6.
- Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. *Gastroenterology* 1997;112:64–72.
- Spitzer C, Brandl S, Rose HJ, Nauck M, Freyberger HJ. Gender-specific association of alexithymia and norepinephrine/cortisol ratios. A preliminary report. *J Psychosom Res* 2005;59:73–6.
- Subic-Wrana C, Bruder S, Thomas W, Lane RD, Kohle K. Emotional awareness deficits in inpatients of a psychosomatic ward: a comparison of two different measures of alexithymia. *Psychosom Med* 2005;67:483–9.
- Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme Medical; 1988.
- Taylor GJ. Recent developments in alexithymia theory and research. *Can J Psychiatry* 2000;45:134–42.
- Taylor GJ, Bagby RM, Parker JDA. Disorder of affect regulation: alexithymia in medical and psychiatric illness. New York: Cambridge University Press; 1997.
- Taylor GJ, Bagby RM, Parker JD. The 20-item Toronto Alexithymia Scale. IV. Reliability and factorial validity in different languages and cultures. *J Psychosom Res* 2003;55:277–83.
- van Kerkhoven LA, van Rossum LG, van Oijen MG, Tan AC, Wittman EM, Laheij RJ, et al. Alexithymia is associated with gastrointestinal symptoms, but does not predict endoscopy outcome in patients with gastrointestinal symptoms. *J Clin Gastroenterol* 2006;40:195–9.
- Vogt BA. Pain and emotion interactions in subregions of the cingulate gyrus. *Nat Rev Neurosci* 2005;6:533–44.

Role of histaminergic neurons in hypnotic modulation of brain processing of visceral perception

S. WATANABE, T. HATTORI, M. KANAZAWA, M. KANO & S. FUKUDO

Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Abstract Modulating visceral sensation of the body is important to the understanding of emotion formation. Molecules that act during hypnosis and modify visceral pain perception are not known. We tested our hypothesis that hypnotic suggestion changes electrophysiological processing of viscerosensory signals in the human brain and that these conditions are in part dependent on histaminergic neurons. Twelve healthy male subjects were studied on two separate days: a day of treatment with histamine H₁ receptor antagonist (*d*-chlorpheniramine 100 µg kg⁻¹, intravenously) and another day of that with placebo (saline, the same amount) in a randomized order. We recorded cortical evoked potentials to 100 rectal electrical stimuli after neutral, hyperalgesic or analgesic hypnotic suggestions as given to modulate the visceral perception. Analgesic suggestion reduced the amplitude of the deepest positive peak of viscerosensory evoked potential. Administration of histamine H₁ antagonist diminished the attenuation of viscerosensory evoked potential by analgesic suggestion. Our results suggest that central pain modulatory system in the brain is activated by hypnotic suggestion and that brain histamine is a mediator in the hypnotic modulation of visceral sensory pathway as well as in the control of consciousness level. These findings lead us to possible new treatment for control of visceral perception.

Keywords central pain modulatory system, cerebral evoked potential, histamine H₁ receptor, hypnotic suggestion, visceral hypersensitivity, visceral perception.

Address for correspondence

Shin Fukudo MD, PhD, Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan.

Tel: +81 22 717 8214; fax: +81 22 717 8161;

e-mail: sfukudo@mail.tains.tohoku.ac.jp

Received: 27 February 2007

Accepted for publication: 25 April 2007

Abbreviations ACC, anterior cingulate cortex; ANOVA, analysis of variance; CEP, cerebral evoked potential; CNS, central nervous system; EEG, electroencephalogram; H₁R, histamine H₁ receptor; HGSHS-A, the Harvard Group Scale of Hypnotic Susceptibility, Form A; N1, the first negative peak; N2, the second negative peak; P1, the first positive peak; PAG, periaqueductal grey.

INTRODUCTION

Interoception and emotion are known to play a crucial role in a number of pathophysiological conditions, including irritable bowel syndrome, a functional gastrointestinal disorder characterized by chronic abdominal pain and discomfort.¹ The neurophysiological mechanisms that underlies the modulation of visceral hypersensitivity remains unclear.²

Hypnosis and placebo have been reported to induce certain expectation of pain modulation.³ Studies examining brain activity have reported that hypnosis⁴ and placebo^{5,6} trigger descending opioidergic and non-opioidergic pain modulatory systems. In addition, hypnotic suggestion has been shown to reduce pain by activation of an endogenous pain inhibitory signal, which descends to the spinal cord and prevents the transmission of pain-related information.⁷ On the other hand, Rainville *et al.*⁴ have found significantly increased activity of the anterior cingulate cortex (ACC) during hypnotic suggestion of increasing pain. In the pain modulatory system, not only endogenous opioid peptides but also other non-opioid mediators are known to be involved.⁸

Neuronal histamine is one of the important mediators of both peripheral and central pain sensitization. The descending histaminergic neurons originate from the hypothalamus and terminate at the periaqueductal grey (PAG) and the dorsal horn of the spinal cord.⁹ In earlier studies, highly selective histamine H₁ receptor (H₁R) agonists have been shown to induce hypernociceptive response,¹⁰ whereas H₁R antagonists have been demonstrated to reduce histamine-induced pain

in experimental models.^{11,12} In addition, it has been reported that H₁ receptor knockout mice display lower sensitivity to pain than normal mice.¹³ These findings suggest that histamine in the central nervous system (CNS) is a dominantly pronociceptive neurotransmitter via the H₁ receptor.

Recording of the cerebral evoked potentials (CEP) is a non-invasive technique, commonly used to investigate the CNS processing of information during activation of peripheral nerves.¹⁴ Cerebral evoked potential has been used to investigate CNS processing of visceral sensation and a highly reproducible recording has been established.^{15,16} This is critically important because exogenous (stimuli-dependent) and endogenous (stimuli-independent) components of pain processing occur in different time windows.¹⁷ Therefore, CEP is an appropriate method for detection of fine changes in the time-dependent domain of central processing of visceral perception.

To investigate the role of neuronal histamine in brain processing of visceral perception during hypnotic analgesia or hyperalgesia, we examined in this study the following hypotheses:

- 1 Hypnotic suggestion modulates brain processing of viscerosensory signals recorded by CEP.
- 2 Blockage of the H₁R enhances the analgesic effects and attenuates the hyperalgesic effects of visceral perception by hypnotic suggestion.

MATERIALS AND METHODS

Subjects

Twelve healthy subjects were enrolled in this study. Subjects consisted of men with a mean age of 21.3 ± 0.6 years. All subjects' healthcare status were checked before enrolment, who had no symptoms or history of major diseases. This study was approved by the Ethics Committee of Tohoku University School of Medicine, and all subjects in the study gave their written informed consent.

Cannulation and recording assemblies

At 9:00 on the experimental day, each subject ingested a preparation consisting of 2000 mL solution of sodium chloride (2.93 g), potassium chloride (1.485 g), sodium carbohydrate (3.37 g), sodium sulphate (11.37 g) and polyethylene glycol 4000. At 12:00, a bipolar electrode catheter (6F, Dr Osypica GMBH, Granzach-Wyhlen, Germany) connected to an electronic stimulator (NEC San-Ei Instruments Ltd, Tokyo, Japan) was inserted 15 cm into the rectum from the anal verge. The two

poles of the electrode were situated 10 mm apart. A polytetra-fluoroethylene cannula was inserted into the left arm vein and saline or *d*-chlorpheniramine was infused at a speed of 1 mL min⁻¹.

Electrical stimulation of the rectum and CEP

The methods for taking viscerosensory CEP were already described elsewhere.^{18,19} In brief, electrical stimulation was applied to the rectal mucosa with a square of 200 μ s duration at a frequency of approximately 1.0 Hz and an intensity ranging from 0 to 50 mA. After measurement of sensory thresholds, each electrical stimulation was performed randomly 100 times with an intensity of either 0 mA (sham stimulation) or 30 mA. The intensity of 30 mA was chosen high enough to evoke visceral perception in most subjects.¹⁹

Silver-silver chloride surface electrodes were applied to the scalp with electrode paste (Elefix, Nihon Kohden, Tokyo, Japan). The active electrode was positioned at Cz (vertex), using the international 10-20 system of electroencephalogram (EEG) electrode placement.²⁰ Cz was chosen because previous topographic mapping studies have shown this to be the site where all components of CEP are adequately recorded.²¹ A reference electrode was positioned on the left ear lobe, and a ground electrode was placed on the neck. Scalp electrodes impedance was <5 k Ω throughout the study. Signal of EEG and electrical stimulation of the rectum were simultaneously recorded with an amplifier and on a data recorder (XR-510; TEAC, Tokyo, Japan). The recordings were performed in a temperature-controlled (25 °C) quiet room on subjects in the supine position, who were asked to open their eyes and minimize eye blinks and movements.

A signal processor (7T18, NEC Sanei Instruments Ltd) and a computer program (EPLYZER version 2.0; Kissei Comtec Co., Matsumoto, Japan) were used for data analysis. The amplifier gain was set at 100 000, and the recording sensitivity was 50 μ V. The bandpass filter settings were 1–100 Hz, and a 50 Hz notch filter was used to reduce interference from the main electrical supply. The sampling rate was 2500 Hz, and the recording epoch was 800 ms in duration. The first 100 ms of the epoch was the prestimulation time. An automatic artefact reject was used to prevent contamination from eye blinks and movements. After each stimulus, individual epochs of data were saved, and the average of the run could be viewed during acquisition. The CEP peaks were evaluated by visual inspection and were designated as a first negative peak (N1), first positive peak (P1), second negative peak (N2), etc.,

numbered in order of occurrence. Criteria for the existence of a particular peak were that the response was reproducible and consistently present in most of the subjects. Classification of a particular peak depended on the proximity to the mean latency. Besides, in this study we focused on the hypnotic modulation of pain affect processing (endogenous components), so the early components of CEP (exogenous components) were omitted in this report.⁴

Hypnotic induction and suggestions

The instructions for hypnotic induction were taken from the Harvard Group Scale of Hypnotic Susceptibility, Form A (HGSHS-A).²² This standardized measure has excellent test-retest reliability after long intervals.²² Indirect suggestions for modulation of pain affect (increase: hyperalgesic; decrease: analgesic) were adapted from Rainville *et al.*²³ The neutral suggestion consisted of the same syllables as the hyperalgesic or the analgesic suggestion but with meaningless words.

Experimental design

Following cannulation, the subjects were allowed 30 min for adaptation. Next, either 100 $\mu\text{g kg}^{-1}$ of *d*-chlorpheniramine or the same amount of saline was then administered to each subject. All subjects were studied for 2 days with at least 1 month between visits, and received during each visit either *d*-chlorpheniramine or saline in a randomized order. Subjects were not informed of the timing of administration of *d*-chlorpheniramine.

The experiment consisted of three stages: baseline, hypnotic induction and electrical stimulation with hypnotic suggestion. After baseline measurement, subjects received hypnotic induction according to a standard method.²³ Subjects received electrical stimulation with 30 mA and sham stimulation with 0 mA under three hypnotic conditions (neutral, hyperalgesic, or analgesic) at random. Before each CEP recording, subjects were given the neutral, hyperalgesic, or analgesic suggestion for neutralizing, increasing, or decreasing abdominal pain affect respectively.

Subjects rated both intensity of abdominal pain and unpleasantness of abdominal pain using the ordinate scale from 0 (none) to 10 (maximum) immediately after each condition.²⁴

Data analysis

For CEP data and visceral perception data acquired under each condition, a multivariate repeated meas-

ures analysis of variance [ANOVA: stimulation (0 mA vs 30 mA) \times suggestion (neutral vs hyperalgesic vs analgesic) \times drug (saline vs *d*-chlorpheniramine) as within subject] was conducted. *Post hoc* test was performed when the significant main effect or interaction were detected in ANOVAs. Furthermore, to test the strength of the relation between subjective visceral sensation and electrophysiological properties of the CEP components, regression analyses of the unpleasantness ratings and the CEP components across all participants were performed. After removing effects due to interpersonal variability, the residual variance in CEP components and unpleasantness rating were analysed for correlation analyses.⁴ Values in the text were expressed as mean \pm standard error. The level of significance was set at a *P*-value < 0.05 .

RESULTS

Effect of hypnotic suggestion on visceral perception

Hypnotic suggestion dramatically changed the form of CEP in healthy subjects (Fig. 1A). Compared with neutral suggestion, analgesic suggestion dampened CEP amplitude, whereas hyperalgesic suggestion did not change it (Fig. 1A). Cerebral evoked potential was triphasic and consisted of N1, P1 and N2. Analgesic suggestion induced a significant decrease in CEP amplitude of the P1–N2 component [$F(2,20) = 3.71$, $P = 0.043$] (Fig. 2B) but not in that of the N1–P1 component (Fig. 2A). On the other hand, hyperalgesic suggestion resulted no significant change in CEP amplitude in both the N1–P1 and P1–N2 components. The latency of the N1, P1 and N2 components was not different amongst the three hypnotic suggestions (Fig. 3A,B).

The subjects rated sham stimulation with 0 mA as no or weak sensation and showed no significant difference in visceral perception to the sham stimulation amongst the three hypnotic suggestions (neutral: 0.5 ± 1.0 ; hyperalgesic: 0.8 ± 1.2 ; analgesic: 0.2 ± 0.4). On the other hand, the stimulus with 30 mA induced moderate sensation and unpleasantness in the subjects. More importantly, both unpleasantness of pain [$F(2,44) = 17.91$, $P < 0.0001$] and its intensity [$F(2,44) = 10.00$, $P < 0.001$] were significantly enhanced by the hyperalgesic suggestion, but attenuated by the analgesic suggestion (Fig. 4A,B).

For hyperalgesic effects, we found that the N1–P1 and P1–N2 amplitude was positively correlated (N1–P1: Pearson's correlation coefficient, $r = 0.687$, $P = 0.001$; P1–N2: $r = 0.650$, $P = 0.001$), and the N1




Figure 1 The grand mean averaged cerebral evoked potential responses to electrical stimulation of the rectum with 30 mA from (A) 12 healthy subjects treated with placebo and (B) 12 healthy subjects treated with *d*-chlorpheniramine. Each line indicates the effects of a suggestion under hypnosis (black line, neutral suggestion; red line, hyperalgesic suggestion; and green line, analgesic suggestion).

latency was negatively correlated with the unpleasantness rating ($r = -0.514$, $P = 0.012$). For analgesic effects, we also found that the N1–P1 and P1–N2 amplitude was positively correlated (N1–P1: Pearson's correlation coefficient, $r = 0.828$, $P < 0.001$; P1–N2: $r = 0.850$, $P < 0.001$), and the N1 latency was negatively correlated with the unpleasantness rating ($r = -0.608$, $P = 0.002$).

Effect of histamine H₁R blockage on hypnotic modulation of visceral perception

Blockage of the H₁R remarkably changed the morphology of CEP in the healthy subjects (Fig. 1B). The reduction in CEP amplitude induced by analgesic suggestion after treatment with placebo was reversed when *d*-chlorpheniramine was administered. The P1–N2 component of CEP amplitude (Fig. 2B) showed significant effect of drug \times suggestion interaction as indicated by ANOVA [$F(2,22) = 3.40$, $P = 0.033$]. In H₁R blockage condition, analgesic suggestion failed to reduce the P1–N2 amplitude ($P = 0.302$) but hyperal-




Figure 2 The amplitude (μV) of cerebral evoked potential (CEP) components after electrical stimulation of the rectum with 30 mA. (A) The N1–P1 amplitude and (B) P1–N2 amplitude of rectal CEP in placebo condition and *d*-chlorpheniramine condition. ^aDenotes a significant decrease in amplitude compared with neutral suggestion ($P = 0.043$). ^bDenotes a significant increase in amplitude compared with neutral suggestion ($P = 0.007$). 30N: neutral, 30H: hyperalgesic, 30A: analgesic, suggestion with 30 mA. Values are expressed as mean \pm SE.

gesic suggestion induced a significant increase in the P1–N2 amplitude ($P = 0.007$). ANOVA of the N1–P1 amplitude showed no significant effect of *d*-chlorpheniramine (Fig. 2A). A significant main effect of drug on the P1 latency was observed by ANOVA, indicating a shorter latency with *d*-chlorpheniramine than with placebo [$F(1,11) = 7.74$, $P = 0.018$] (Fig. 3B). ANOVA showed tendency of shorter N1 latency as the marginal main effect of drug [$F(1,11) = 4.58$, $P = 0.056$] (Fig. 3A). ANOVA of the N2 latency showed no significant effect of *d*-chlorpheniramine (Fig. 3C).

For subjective visceral perception, no significant effect of drug or drug \times suggestion interaction on unpleasantness of pain or intensity of pain was observed (Fig. 4A,B). However, compared with the placebo condition, the H₁R blockage condition attenuated the analgesic effect in subjective unpleasantness. Indeed, independent *t*-analysis showed significant difference between the neutral and analgesic suggestion




Figure 3 The latency (ms) of cerebral evoked potential (CEP) components after electrical stimulation of the rectum with 30 mA. (A) The N1 latency, (B) P1 latency and (C) N2 latency of rectal CEP in placebo condition and *d*-chlorpheniramine condition. 30N: neutral, 30H: hyperalgesic, 30A: analgesic, suggestion with 30 mA. Values are expressed as mean ± SE.

with the placebo condition [$t(44) = 2.17, P = 0.036$] but not the H₁R blockage condition [$t(44) = 0.48, P = 0.634$] [Fig. 4B].




Figure 4 The ordinate scale (0–10) of visceral perception to electrical stimulation of the rectum with 0 mA or 30 mA. (A) The pain intensity, (B) pain unpleasantness in ordinate scales in placebo condition and *d*-chlorpheniramine condition. ^cDenotes significant changes compared with neutral suggestion ($P < 0.001$). ON: neutral, OH: hyperalgesic, OA: analgesic, suggestion with 0 mA (sham stimulation), 30N: neutral, 30H: hyperalgesic, 30A: analgesic, suggestion with 30 mA. Values are expressed as mean ± SE.

Threshold of electrical stimulation of the rectum

Threshold of the electrical stimulation of the rectum indicated as follows; sensation: 16.8 ± 1.9 mA, discomfort: 28.7 ± 2.5 mA and pain: 37.4 ± 2.0 mA.

DISCUSSION

This study is the first to show that hypnotic suggestion changes electrophysiological processing of visceral perception in the human brain under normal visceral states and that this change is at least in part dependent on neuronal histamine. Visceral perception has long been believed to be a consciously uncontrollable